NCT06901349

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Bimagrumab	Administered SC
DRUG	Tirzepatide	Administered SC
DRUG	Bimagrumab Placebo	Administered SC
DRUG	Tirzepatide Placebo	Administered SC

Timeline

• Start date: 2025-05-23
• Primary completion: 2025-06-10
• Completion: 2025-06-10
• First posted: 2025-03-28
• Last updated: 2025-09-24

Locations

50 sites across 5 countries: United States, Argentina, Canada, China, Japan

Regulatory

• FDA-regulated drug study